Therapeutic ChallengesPulmonary Hypertension and Atrial Septal Defect: Management DilemmaEl-Kersh, Karim MD1; Howsare, Molly DO1; Zaidi, Ali MD2; Flaherty, Michael P. MD, PhD3; Smith, J. Shaun DO1 Author Information 1Department of Medicine, Division of Pulmonary, Critical Care and Sleep Disorders Medicine, University of Louisville, Louisville, KY; 2Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; and 3Department of Medicine, Division of Cardiology, University of Louisville, Louisville, KY. *Address for correspondence: Department of Medicine, Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Ambulatory Care Building, 550 S. Jackson St, Louisville, KY 40202. E-mail: [email protected] The authors have no conflicts of interest to declare. American Journal of Therapeutics: September/October 2017 - Volume 24 - Issue 5 - p e602-e605 doi: 10.1097/MJT.0000000000000472 Buy Metrics Abstract The decision making in patients with an atrial septal defect (ASD) in setting of pulmonary hypertension is complex. In the era of pulmonary arterial vasodilator therapy, every patient should undergo evaluation by pulmonary hypertension experts especially if defect closure is being considered. Defect closure in the inappropriate group can lead to poor outcomes. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.